Design Therapeutics, Inc.

NASDAQ:DSGN

Biotechnology

Healthcare
$9.84 +1.59%

+$0.19 today

Market cap
$630.12M
Beta
1.66
P/E (TTM)
-10.7
EPS (TTM)
-$1.13
52W Low $3.33High $17.25

Volume 0.29M

Average 0.74M

Returns on capital

Design Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-32.8%

avg 3.3%

ROIC

-37.1%

avg -11.5%

ROA

-30.9%

avg -342.6%

Analysis

ROA is currently the strongest return metric at -30.9% versus its period average of -342.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Pratik Shah

Co-Founder, President, Chief Executive Officer, Principal Financial Officer & Executive ChairpersonUSD 790K56750.00K1.20%

Sean Jeffries

Chief Operating OfficerUSD 698K46375.00K0.60%

Chris Storgard

Chief Medical OfficerUSD 633.76K60250.00K0.40%

Doane Chilcoat

Chief Technology Officer————

Jim Kerr

Chief of Manufacturing & Product Development————

Julie D. Burgess

Chief Accounting Officer————

Aseem Z. Ansari

Co-Founder & Scientific Advisor——100.00K0.16%

Tadimeti S. Rao

Chief Scientific Officer————

Mustapha Parekh

General Counsel————

Chengzhi Zhang

Chief Chemist————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 2, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Design Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about DSGN's management, answered from reported figures.

Who manages DSGN?

Design Therapeutics, Inc. (DSGN) lists 10 active executives. The top listed executive is Doane Chilcoat, Chief Technology Officer.

Are DSGN insiders buying or selling?

Recent insider activity shows net buying of $134.28M.